Operating Income (Loss) of ELITE PHARMACEUTICALS INC /NV/ from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Operating Income (Loss) in USD history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Income (Loss) for the quarter ending 31 Dec 2025 was $9,012,943, a 721% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Income (Loss) for the twelve months ending 31 Dec 2025 was $50,080,055, a 311% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Operating Income (Loss) for 2024 was $19,600,468, a 82% increase from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Operating Income (Loss) for 2023 was $10,788,769, a 193% increase from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Operating Income (Loss) for 2022 was $3,676,002, a 28% decline from 2021.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $50,080,055 $9,012,943 +$7,915,133 +721% 01 Oct 2025 31 Dec 2025 10-Q 17 Feb 2026 2026 Q3
Q3 2025 $42,164,922 $8,213,746 +$4,728,803 +136% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2026 Q2
Q2 2025 $37,436,119 $21,699,707 +$17,835,651 +462% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q1 2025 $19,600,468 $11,153,659 +$7,425,075 +199% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025 2025 FY
Q4 2024 $12,175,393 $1,097,810 -$2,434,846 -69% 01 Oct 2024 31 Dec 2024 10-Q 17 Feb 2026 2026 Q3
Q3 2024 $14,610,239 $3,484,943 +$1,559,438 +81% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2026 Q2
Q2 2024 $13,050,801 $3,864,056 +$2,262,032 +141% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2026 Q1
Q1 2024 $10,788,769 $3,728,584 +$4,115,483 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q4 2023 $6,673,286 $3,532,656 +$1,573,556 +80% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2025 Q3
Q3 2023 $5,099,730 $1,925,505 +$844,388 +78% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2025 Q2
Q2 2023 $4,255,342 $1,602,024 +$579,340 +57% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2025 Q1
Q1 2023 $3,676,002 $386,899 -$1,238,574 -145% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024 2024 FY
Q4 2022 $4,914,576 $1,959,100 +$127,800 +7% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q3
Q3 2022 $4,786,776 $1,081,117 -$341,460 -24% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q2
Q2 2022 $5,128,236 $1,022,684 +$57,526 +6% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2024 Q1
Q1 2022 $5,070,710 $851,675 +$1,919,178 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023 2023 FY
Q4 2021 $3,151,532 $1,831,300 +$830,131 +83% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023 2023 Q3
Q3 2021 $2,321,401 $1,422,577 +$82,320 +6.1% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2023 Q2
Q2 2021 $2,239,081 $965,158 +$134,558 +16% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2023 Q1
Q1 2021 $2,104,523 $1,067,503 +$306,863 +22% 01 Jan 2021 31 Mar 2021 10-K 29 Jun 2022 2022 FY
Q4 2020 $1,797,660 $1,001,169 +$309,974 +45% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2022 Q3
Q3 2020 $1,487,686 $1,340,257 +$1,794,789 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q2
Q2 2020 $307,103 $830,600 +$1,978,305 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2022 Q1
Q1 2020 $2,285,408 $1,374,366 +$635,838 +32% 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021 2021 FY
Q4 2019 $2,921,246 $691,195 +$3,328,325 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q3
Q3 2019 $6,249,571 $454,532 +$2,198,440 +83% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2021 Q2
Q2 2019 $8,448,011 $1,147,705 +$710,689 +38% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2021 Q1
Q1 2019 $9,158,700 $2,010,204 +$612,796 +23% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q4 2018 $9,771,496 $2,637,130 -$578,169 -28% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020 2020 Q3
Q3 2018 $9,193,327 $2,652,972 -$523,101 -25% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2020 Q2
Q2 2018 $8,670,226 $1,858,394 +$379,877 +17% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2020 Q1
Q1 2018 $9,050,103 $2,623,000 +$567,000 +18% 01 Jan 2018 31 Mar 2018 10-K 14 Jun 2018 2018 FY
Q4 2017 $9,617,103 $2,058,961 -$336,961 -20% 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019 2019 Q3
Q3 2017 $9,280,142 $2,129,871 -$924,871 -77% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2019 Q2
Q2 2017 $8,355,271 $2,238,271 -$1,000,271 -81% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2019 Q1
Q1 2017 $7,355,000 $3,190,000 -$3,761,000 -659% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018 2018 FY
Q4 2016 $3,594,000 $1,722,000 +$991,000 +37% 01 Oct 2016 31 Dec 2016 10-K 14 Jun 2018 2018 FY
Q3 2016 $4,585,000 $1,205,000 +$2,562,000 +68% 01 Jul 2016 30 Sep 2016 10-K 14 Jun 2018 2018 FY
Q2 2016 $7,147,000 $1,238,000 +$1,169,000 +49% 01 Apr 2016 30 Jun 2016 10-K 14 Jun 2018 2018 FY
Q1 2016 $8,316,000 $571,000 +$6,028,000 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018 2018 FY
Q4 2015 $14,344,000 $2,713,000 -$156,000 -6.1% 01 Oct 2015 31 Dec 2015 10-K 14 Jun 2018 2018 FY
Q3 2015 $14,188,000 $3,767,000 +$294,000 +7.2% 01 Jul 2015 30 Sep 2015 10-K 14 Jun 2018 2018 FY
Q2 2015 $14,482,000 $2,407,000 +$2,024,000 +46% 01 Apr 2015 30 Jun 2015 10-K 14 Jun 2018 2018 FY
Q1 2015 $16,506,000 $5,457,000 -$3,073,000 -129% 01 Jan 2015 31 Mar 2015 10-K 14 Jun 2017 2017 FY
Q4 2014 $13,433,000 $2,557,000 -$1,320,000 -107% 01 Oct 2014 31 Dec 2014 10-K 14 Jun 2017 2017 FY
Q3 2014 $12,113,000 $4,061,000 -$3,374,000 -491% 01 Jul 2014 30 Sep 2014 10-K 14 Jun 2017 2017 FY
Q2 2014 $8,739,000 $4,431,000 -$3,455,000 -354% 01 Apr 2014 30 Jun 2014 10-K 14 Jun 2017 2017 FY
Q1 2014 $5,284,000 $2,384,000 -$2,096,107 -728% 01 Jan 2014 31 Mar 2014 10-K 15 Jun 2016 2016 FY
Q4 2013 $3,187,893 $1,237,000 -$962,790 -351% 01 Oct 2013 31 Dec 2013 10-K 15 Jun 2016 2016 FY
Q3 2013 $2,225,103 $687,000 -$171,732 -33% 01 Jul 2013 30 Sep 2013 10-K 15 Jun 2016 2016 FY
Q2 2013 $2,053,371 $976,000 -$490,238 -101% 01 Apr 2013 30 Jun 2013 10-K 15 Jun 2016 2016 FY
Q1 2013 $1,563,133 $287,893 +$319,161 +53% 01 Jan 2013 31 Mar 2013 10-K 30 Jun 2014 2014 FY
Q4 2012 $1,882,294 $274,210 +$156,740 +36% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2013 Q3
Q3 2012 $2,039,034 $515,268 +$76,334 +13% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q2
Q2 2012 $2,115,368 $485,762 -$149,230 -44% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q1
Q1 2012 $1,966,138 $607,054 +$118,061 +16% 01 Jan 2012 31 Mar 2012 10-K 21 Jun 2013 2012 FY
Q4 2011 $2,084,199 $430,950 -$503,881 -691% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013 2012 Q3
Q3 2011 $1,580,318 $591,602 -$454,795 -332% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012 2012 Q2
Q2 2011 $1,125,523 $336,532 -$239,763 -248% 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012 2012 Q1
Q1 2011 $885,760 $725,115 01 Jan 2011 31 Mar 2011 10-K 29 Jun 2012 2011 FY
Q4 2010 $72,931 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012 2011 Q3
Q3 2010 $136,807 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011 2011 Q2
Q2 2010 $96,769 01 Apr 2010 30 Jun 2010 10-Q/A 19 Aug 2011 2011 Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $19,600,468 +$8,811,699 +82% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025 2025 FY
2023 $10,788,769 +$7,112,767 +193% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025 2025 FY
2022 $3,676,002 -$1,394,708 -28% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024 2024 FY
2021 $5,070,710 +$2,966,187 +141% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023 2023 FY
2020 $2,104,523 +$4,389,931 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022 2022 FY
2019 $2,285,408 +$6,873,292 +75% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021 2021 FY
2018 $9,158,700 -$107,421 -1.2% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $9,051,279 -$1,695,346 -23% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019 2019 FY
2016 $7,355,933 +$960,867 +12% 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018 2018 FY
2015 $8,316,800 +$8,190,172 +50% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018 2018 FY
2014 $16,506,972 -$11,223,348 -212% 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017 2017 FY
2013 $5,283,624 -$3,720,491 -238% 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016 2016 FY
2012 $1,563,133 +$403,005 +20% 01 Apr 2012 31 Mar 2013 10-K 30 Jun 2014 2014 FY
2011 $1,966,138 -$1,080,378 -122% 01 Apr 2011 31 Mar 2012 10-K 21 Jun 2013 2012 FY
2010 $885,760 01 Apr 2010 31 Mar 2011 10-K 29 Jun 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.